Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol sees Medarex acquisition as a way to expand its immunology and oncology pipeline in preparing for Plavix generics in 2012.
You may also be interested in...
Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono
In a transaction that involves no cash moving in either direction, Bristol-Myers Squibb has expanded its territorial rights to an oncology antibody acquired in its 2009 purchase of Medarex, while Ono Pharmaceutical gets co-development and co-commercialization rights to rheumatoid arthritis drug Orencia (abatacept) in Japan
Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono
Rather than financial considerations, Ono Pharmaceutical will receive co-development and co-commercialization rights to rheumatoid arthritis drug Orencia in Japan.
Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono
Rather than financial considerations, Ono Pharmaceutical will receive co-development and co-commercialization rights to rheumatoid arthritis drug Orencia in Japan.